Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) dropped 9.5% on Tuesday . The stock traded as low as $13.04 and last traded at $13.04. Approximately 735,392 shares were traded during trading, a decline of 15% from the average daily volume of 869,654 shares. The stock had previously closed at $14.41.
Analyst Ratings Changes
NAGE has been the topic of several research reports. Roth Capital restated a "buy" rating and set a $23.00 price target (up from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th. Wall Street Zen raised Niagen Bioscience from a "buy" rating to a "strong-buy" rating in a report on Sunday, June 22nd. Finally, Canaccord Genuity Group upped their target price on Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th.
Read Our Latest Stock Report on NAGE
Niagen Bioscience Stock Performance
The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of 75.65 and a beta of 2.14. The firm's 50-day moving average price is $11.08 and its two-hundred day moving average price is $7.70.
Niagen Bioscience Company Profile
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Read More
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
